Bevacizumab-Enhanced Chemotherapy for Metastatic Colorectal Cancer

Bevacizumab, a humanised monoclonal antibody targeting vascular endothelial growth factor (VEGF), has become integral to the management of metastatic colorectal cancer (mCRC). By binding VEGF and preventing its interaction with endothelial receptors, bevacizumab disrupts tumour angiogenesis, normalises the aberrant vasculature and enhances delivery of cytotoxic agents. In combination with fluoropyrimidine-, oxaliplatin- or irinotecan-based regimens, bevacizumab has demonstrated improvements in response rates, progression-free survival and overall survival compared with chemotherapy alone. These benefits, however, must be balanced against increased risks of hypertension, thromboembolic events, proteinuria and, in rare cases, gastrointestinal perforation or haemorrhage. Contemporary research seeks to refine patient selection through biomarker discovery, to optimise sequencing with other targeted therapies or immune checkpoint inhibitors, and to overcome resistance driven by vascular heterogeneity and adaptive pro-angiogenic signalling. The global significance of bevacizumab-enhanced chemotherapy lies in its proven capacity to extend life expectancy and to establish angiogenesis inhibition as a cornerstone of personalised treatment for colorectal malignancies.

Research from Nature Portfolio

A large retrospective analysis of patients with stage IV colorectal cancer treated with first-line bevacizumab-containing chemotherapy has shown that efficacy is not significantly influenced by KRAS mutation status or tumour sidedness. Objective response rates and disease control rates were comparable between KRAS-mutant and wild-type cohorts, with median progression-free intervals and overall survival times remaining consistent across molecular subgroups. These findings reinforce the broad applicability of bevacizumab-enhanced regimens and suggest that current molecular markers used to guide selection of anti-EGFR agents may not constrain the benefits of angiogenesis inhibition.

Bevacizumab-Enhanced Chemotherapy for Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in bevacizumab-enhanced chemotherapy for metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Monoclonal antibody: A laboratory-produced molecule engineered to bind specifically to a target antigen, such as VEGF, to inhibit its biological function.

Vascular endothelial growth factor (VEGF): A signalling protein that promotes growth and survival of blood vessels within tumours, facilitating angiogenesis.

Angiogenesis: The process by which new blood vessels form from pre-existing vasculature, crucial for tumour growth and metastasis.

Progression-free survival (PFS): The length of time during and after treatment in which a patient’s disease does not worsen.

Overall survival (OS): The duration from initiation of therapy until death from any cause, a key measure of treatment benefit.

References

1. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer (2016).
2. KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. Scientific Reports (2017).
3. Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database. Frontiers in Pharmacology (2024).
4. Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. Cancers (2024).
5. Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment. Pharmaceuticals (2025).